Research Specialties (Reported growth- Q3: 11.8%, YTD: 14.1%; Organic growth- Q3: 8.2%, YTD: 7.5%): This unit continued its strong performance in Q3 2008 with run rate growth exceeding its 6% long-term organic growth target for the ninth consecutive quarter. Improved demand from the academic sector in all geographic markets continued and sales to pharmaceutical customers in CAPLA countries rebounded in Q3 2008. Growth also benefited from new service initiatives launched earlier in the year and recent new product introductions of ultrapure proteins and chiral products.
Research Essentials (Reported growth- Q3: 8.6%, YTD: 10.9%; Organic growth- Q3: 5.3%, YTD: 4.6%): Q3 2008 organic sales growth continued the pattern of exceeding expectations in each of the last six quarters. Strong sales gains of research-based cell culture products were helped by continued improvement in sales to academic accounts in all geographic regions.
Research Biotech (Reported growth- Q3: 9.7%, YTD: 14.7%; Organic growth- Q3: 6.5%, YTD: 8.5%): Continued stronger spending by academic customers worldwide enhanced sales growth for molecular biology and cell signaling products. This was partially offset by the discontinuation of selected custom peptide and antisera products to enable us to focus on other more promising business areas, including custom peptide libraries, in an effort to enhance an already strong market position, new genomics and proteomics kits and the continued addition of new antibody products. Average pricing for synthetic DNA products improved in Q3 2008 over that realized in the first half of 2008 as demand for modified products increased.
SAFC (Reported growth- Q3: 0.3%, YTD: 9.4%; Organic growth- Q3: (2.0)%,
YTD: 3.6%): Continued strong growth in Hitech products matched with steady
growth for Supply Solutions and Biosciences products was offset by r
Copyright©2008 PR Newswire.
All rights reserved